{"transactions":[{"id":737903,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T00:22:28.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders, subject to Dr. Scheiner's continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Under Dr. Scheiner's arrangement with the Adviser, Dr. Scheiner holds the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Scheiner is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."}],"balance_after":22100,"derivative":{"exercise_price":6.63,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0001231919-26-000640","document":"form4-06162026_120622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000123191926000640/form4-06162026_120622.xml","form_type":"4"}},{"id":737904,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38205,"kind":"person","name":"George Jeffrey P.","position":1,"cik":"0001796789","reported_name":"George Jeffrey P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T00:18:23.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders."}],"balance_after":22100,"derivative":{"exercise_price":6.63,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0001796789-26-000004","document":"wk-form4_1781569101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000179678926000004/wk-form4_1781569101.xml","form_type":"4"}},{"id":737902,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T00:18:17.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders."}],"balance_after":22100,"derivative":{"exercise_price":6.63,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0001340881-26-000001","document":"wk-form4_1781569095.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000134088126000001/wk-form4_1781569095.xml","form_type":"4"}},{"id":737901,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38203,"kind":"person","name":"MCCOLLUM JAMES W","position":1,"cik":"0001200889","reported_name":"MCCOLLUM JAMES W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T00:18:12.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders."}],"balance_after":22100,"derivative":{"exercise_price":6.63,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0001200889-26-000001","document":"wk-form4_1781569089.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000120088926000001/wk-form4_1781569089.xml","form_type":"4"}},{"id":737900,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":36311,"kind":"person","name":"Thunen Shelley B","position":1,"cik":"0001297491","reported_name":"Thunen Shelley B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T00:18:06.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders."}],"balance_after":22100,"derivative":{"exercise_price":6.63,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0001297491-26-000001","document":"wk-form4_1781569084.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000129749126000001/wk-form4_1781569084.xml","form_type":"4"}},{"id":737899,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":20769,"kind":"person","name":"Guerard Frederic","position":1,"cik":"0001825009","reported_name":"Guerard Frederic","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T00:18:01.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders."}],"balance_after":22100,"derivative":{"exercise_price":6.63,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0001825009-26-000001","document":"wk-form4_1781569078.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000182500926000001/wk-form4_1781569078.xml","form_type":"4"}},{"id":737906,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38207,"kind":"person","name":"Scheiner Zachary","position":1,"cik":"0001816523","reported_name":"Scheiner Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T00:17:55.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock."}],"balance_after":22100,"derivative":{"exercise_price":6.63,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0001816523-26-000005","document":"wk-form4_1781569072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816523/000181652326000005/wk-form4_1781569072.xml","form_type":"4"}},{"id":825310,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38205,"kind":"person","name":"George Jeffrey P.","position":1,"cik":"0001796789","reported_name":"George Jeffrey P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-30T12:47:03.000Z","date":"2026-03-27","kind":"purchase","planned":false,"acquired":true,"shares":5592,"price":8.9217,"value":49890.1464,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 5,592 shares purchased in the price range of $8.80 to $9.12 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":5592,"source":{"system":"sec-edgar","filing":"0001796789-26-000003","document":"wk-form4_1774874821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000179678926000003/wk-form4_1774874821.xml","form_type":"4"}},{"id":825309,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":35188,"kind":"person","name":"Schimmelpennink Evert B.","position":1,"cik":"0001713795","reported_name":"Schimmelpennink Evert B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Secretary"}}],"security":"Common Stock","published_at":"2026-03-30T12:46:58.000Z","date":"2026-03-27","kind":"purchase","planned":false,"acquired":true,"shares":28089,"price":8.9505,"value":251410.5945,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 28,089 shares purchased in the price range of $8.80 to $9.25 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":77289,"source":{"system":"sec-edgar","filing":"0001713795-26-000004","document":"wk-form4_1774874815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000171379526000004/wk-form4_1774874815.xml","form_type":"4"}},{"id":825308,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-30T12:46:52.000Z","date":"2026-03-27","kind":"purchase","planned":false,"acquired":true,"shares":7500,"price":8.57,"value":64275.0,"ownership":{"direct":true},"balance_after":12886,"source":{"system":"sec-edgar","filing":"0001706176-26-000004","document":"wk-form4_1774874809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000170617626000004/wk-form4_1774874809.xml","form_type":"4"}},{"id":946965,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-06T21:21:45.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). \"RSU Grant Date\" shall mean January 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). \"RSU Grant Date\" shall mean January 2, 2026."}],"balance_after":14000,"derivative":{"underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001706176-26-000002","document":"wk-form4_1767734500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000170617626000002/wk-form4_1767734500.xml","form_type":"4"}},{"id":946964,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:21:45.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":84200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean January 2, 2026."}],"balance_after":84200,"derivative":{"exercise_price":16,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":84200},"source":{"system":"sec-edgar","filing":"0001706176-26-000002","document":"wk-form4_1767734500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000170617626000002/wk-form4_1767734500.xml","form_type":"4"}},{"id":946963,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":35188,"kind":"person","name":"Schimmelpennink Evert B.","position":1,"cik":"0001713795","reported_name":"Schimmelpennink Evert B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:21:35.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":358100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean January 2, 2026."}],"balance_after":358100,"derivative":{"exercise_price":16,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":358100},"source":{"system":"sec-edgar","filing":"0001713795-26-000002","document":"wk-form4_1767734492.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000171379526000002/wk-form4_1767734492.xml","form_type":"4"}},{"id":947271,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-06T16:22:01.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). \"RSU Grant Date\" shall mean January 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). \"RSU Grant Date\" shall mean January 2, 2026."}],"balance_after":14000,"derivative":{"underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0002015796-26-000002","document":"wk-form4_1767734519.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000201579626000002/wk-form4_1767734519.xml","form_type":"4"}},{"id":947270,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T16:22:01.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":84200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean January 2, 2026."}],"balance_after":84200,"derivative":{"exercise_price":16,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":84200},"source":{"system":"sec-edgar","filing":"0002015796-26-000002","document":"wk-form4_1767734519.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000201579626000002/wk-form4_1767734519.xml","form_type":"4"}},{"id":947273,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70050,"kind":"person","name":"Odrich Marc","position":1,"cik":"0002015900","reported_name":"Odrich Marc","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-06T16:21:54.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). \"RSU Grant Date\" shall mean January 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). \"RSU Grant Date\" shall mean January 2, 2026."}],"balance_after":14000,"derivative":{"underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0002015900-26-000002","document":"wk-form4_1767734511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2015900/000201590026000002/wk-form4_1767734511.xml","form_type":"4"}},{"id":947272,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70050,"kind":"person","name":"Odrich Marc","position":1,"cik":"0002015900","reported_name":"Odrich Marc","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T16:21:54.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":84200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean January 2, 2026."}],"balance_after":84200,"derivative":{"exercise_price":16,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":84200},"source":{"system":"sec-edgar","filing":"0002015900-26-000002","document":"wk-form4_1767734511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015900/000201590026000002/wk-form4_1767734511.xml","form_type":"4"}},{"id":994154,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-19T19:02:15.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the \"2020 Plan\"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean April 26, 2021."}],"balance_after":53241,"derivative":{"exercise_price":2.08,"expiration_date":"2031-08-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0002015796-25-000003","document":"wk-form4_1763596932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000201579625000003/wk-form4_1763596932.xml","form_type":"4"}},{"id":994153,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-11-19T19:02:15.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":5788,"price":26.3669,"value":152611.6172,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on August 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 5,788 shares sold in the price range of $26.12 to $26.81 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":4733,"source":{"system":"sec-edgar","filing":"0002015796-25-000003","document":"wk-form4_1763596932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000201579625000003/wk-form4_1763596932.xml","form_type":"4"}},{"id":994152,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-11-19T19:02:15.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":4212,"price":25.7385,"value":108410.562,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on August 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 4,212 shares sold in the price range of $25.12 to $26.11 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":10521,"source":{"system":"sec-edgar","filing":"0002015796-25-000003","document":"wk-form4_1763596932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000201579625000003/wk-form4_1763596932.xml","form_type":"4"}},{"id":994151,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-11-19T19:02:15.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":2.08,"value":20800.0,"ownership":{"direct":true},"balance_after":14733,"source":{"system":"sec-edgar","filing":"0002015796-25-000003","document":"wk-form4_1763596932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000201579625000003/wk-form4_1763596932.xml","form_type":"4"}},{"id":1003806,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38203,"kind":"person","name":"MCCOLLUM JAMES W","position":1,"cik":"0001200889","reported_name":"MCCOLLUM JAMES W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-10T21:13:53.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":10500,"price":22.7884,"value":239278.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 10,500 shares purchased in the price range of $22.68 to $22.87 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10500,"source":{"system":"sec-edgar","filing":"0001815776-25-000073","document":"wk-form4_1762809230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000073/wk-form4_1762809230.xml","form_type":"4"}},{"id":1004954,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-08T00:42:43.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":2178,"price":22.7561,"value":49562.7858,"ownership":{"direct":true},"balance_after":5386,"source":{"system":"sec-edgar","filing":"0001815776-25-000072","document":"wk-form4_1762562560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000072/wk-form4_1762562560.xml","form_type":"4"}},{"id":1004953,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-08T00:42:43.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":20,"price":22.71,"value":454.2,"ownership":{"direct":true},"balance_after":3208,"source":{"system":"sec-edgar","filing":"0001815776-25-000072","document":"wk-form4_1762562560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000072/wk-form4_1762562560.xml","form_type":"4"}},{"id":1027461,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-02T20:40:04.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":123,"price":47.0133,"value":5782.6359,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":764127,"source":{"system":"sec-edgar","filing":"0001193125-25-228493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525228493/ownership.xml","form_type":"4"}},{"id":1027460,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-02T20:40:04.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":177,"price":47.0133,"value":8321.3541,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1050599,"source":{"system":"sec-edgar","filing":"0001193125-25-228493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525228493/ownership.xml","form_type":"4"}},{"id":1027459,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-02T20:40:04.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":57502,"price":46.4068,"value":2668483.8136,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":764250,"source":{"system":"sec-edgar","filing":"0001193125-25-228493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525228493/ownership.xml","form_type":"4"}},{"id":1027458,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-02T20:40:04.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":83066,"price":46.4068,"value":3854827.2488,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1050776,"source":{"system":"sec-edgar","filing":"0001193125-25-228493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525228493/ownership.xml","form_type":"4"}},{"id":1027457,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-02T20:40:04.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":34405,"price":45.3547,"value":1560428.4535,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":821752,"source":{"system":"sec-edgar","filing":"0001193125-25-228493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525228493/ownership.xml","form_type":"4"}},{"id":1027456,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-02T20:40:04.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":49701,"price":45.3547,"value":2254173.9447,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1133842,"source":{"system":"sec-edgar","filing":"0001193125-25-228493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525228493/ownership.xml","form_type":"4"}},{"id":1034668,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-22T20:23:19.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":132,"price":43.3,"value":5715.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":856157,"source":{"system":"sec-edgar","filing":"0001193125-25-211363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525211363/ownership.xml","form_type":"4"}},{"id":1034667,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-22T20:23:19.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":268,"price":43.3,"value":11604.4,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1183543,"source":{"system":"sec-edgar","filing":"0001193125-25-211363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525211363/ownership.xml","form_type":"4"}},{"id":1034666,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-22T20:23:19.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":20148,"price":43.0038,"value":866440.5624,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.25 to $43.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":856289,"source":{"system":"sec-edgar","filing":"0001193125-25-211363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525211363/ownership.xml","form_type":"4"}},{"id":1034665,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-22T20:23:19.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":40907,"price":43.0038,"value":1759156.4466,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.25 to $43.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1183811,"source":{"system":"sec-edgar","filing":"0001193125-25-211363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525211363/ownership.xml","form_type":"4"}},{"id":1034664,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-22T20:23:19.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":24370,"price":41.5908,"value":1013567.796,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $41.25 to $42.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":876437,"source":{"system":"sec-edgar","filing":"0001193125-25-211363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525211363/ownership.xml","form_type":"4"}},{"id":1034663,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-22T20:23:19.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":49479,"price":41.5908,"value":2057871.1932,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $41.25 to $42.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1224718,"source":{"system":"sec-edgar","filing":"0001193125-25-211363","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000119312525211363/ownership.xml","form_type":"4"}},{"id":1055814,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-26","kind":"sale","planned":false,"acquired":false,"shares":1707,"price":39.5022,"value":67430.2554,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.49 to $39.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":900807,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055813,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-26","kind":"sale","planned":false,"acquired":false,"shares":3465,"price":39.5022,"value":136875.123,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.49 to $39.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1274197,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055812,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-26","kind":"sale","planned":false,"acquired":false,"shares":21661,"price":38.9744,"value":844224.4784,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.50 to $39.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":902514,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055811,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-26","kind":"sale","planned":false,"acquired":false,"shares":43978,"price":38.9744,"value":1714016.1632,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.50 to $39.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1277662,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055810,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-25","kind":"sale","planned":false,"acquired":false,"shares":1058,"price":39.9212,"value":42236.6296,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.81 to $40.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":924175,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055809,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-25","kind":"sale","planned":false,"acquired":false,"shares":2149,"price":39.9212,"value":85790.6588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.81 to $40.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1321640,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055808,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-25","kind":"sale","planned":false,"acquired":false,"shares":24760,"price":39.5255,"value":978651.38,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.815 to $39.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":925233,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055807,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-25","kind":"sale","planned":false,"acquired":false,"shares":50270,"price":39.5255,"value":1986946.885,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.815 to $39.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1323789,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055806,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":2809,"price":40.5899,"value":114017.0291,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $40.50 to $40.8819, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":949993,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055805,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":5668,"price":40.5899,"value":230063.5532,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $40.50 to $40.8819, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1374059,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055804,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":10076,"price":40.0297,"value":403339.2572,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.5085 to $40.4616, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":952802,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1055803,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T23:59:49.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":20493,"price":40.0297,"value":820328.6421,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.5085 to $40.4616, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1379727,"source":{"system":"sec-edgar","filing":"0000950170-25-111529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025111529/ownership.xml","form_type":"4"}},{"id":1061958,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-19T20:51:33.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":15085,"price":38.5611,"value":581694.1935,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.26 to $39.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":962878,"source":{"system":"sec-edgar","filing":"0000950170-25-110163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025110163/ownership.xml","form_type":"4"}},{"id":1061957,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-19T20:51:33.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":30628,"price":38.5611,"value":1181049.3708,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.26 to $39.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1400220,"source":{"system":"sec-edgar","filing":"0000950170-25-110163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025110163/ownership.xml","form_type":"4"}},{"id":1061956,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-19T20:51:33.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":69949,"price":39.5,"value":2762985.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":977963,"source":{"system":"sec-edgar","filing":"0000950170-25-110163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025110163/ownership.xml","form_type":"4"}},{"id":1061955,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-19T20:51:33.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":145051,"price":39.5,"value":5729514.5,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1430848,"source":{"system":"sec-edgar","filing":"0000950170-25-110163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025110163/ownership.xml","form_type":"4"}},{"id":1088074,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-14T20:50:19.000Z","date":"2025-07-10","kind":"sale","planned":false,"acquired":false,"shares":191376,"price":34,"value":6506784.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1575899,"source":{"system":"sec-edgar","filing":"0000950170-25-095616","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025095616/ownership.xml","form_type":"4"}},{"id":1097972,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-01T22:16:12.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":30.465,"value":6093000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $30.18 to $30.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1767275,"source":{"system":"sec-edgar","filing":"0000950170-25-092373","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025092373/ownership.xml","form_type":"4"}},{"id":1105091,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T21:50:38.000Z","date":"2025-06-20","kind":"sale","planned":false,"acquired":false,"shares":133924,"price":30.25,"value":4051201.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC\nVI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary\ninterests therein."}],"balance_after":1967275,"source":{"system":"sec-edgar","filing":"0000950170-25-088604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025088604/ownership.xml","form_type":"4"}},{"id":1105090,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T21:50:38.000Z","date":"2025-06-20","kind":"sale","planned":false,"acquired":false,"shares":100877,"price":30.35,"value":3061616.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1047912,"source":{"system":"sec-edgar","filing":"0000950170-25-088604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025088604/ownership.xml","form_type":"4"}},{"id":1105089,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T21:50:38.000Z","date":"2025-06-18","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":29.95,"value":2995000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1148789,"source":{"system":"sec-edgar","filing":"0000950170-25-088604","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025088604/ownership.xml","form_type":"4"}},{"id":1113608,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74649,"kind":"organization","name":"Versant Venture Capital VII, L.P.","position":7,"cik":"0001750266","reported_name":"Versant Venture Capital VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74650,"kind":"organization","name":"Versant Ventures VII GP, L.P.","position":8,"cik":"0001777655","reported_name":"Versant Ventures VII GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74651,"kind":"organization","name":"Versant Ventures VII GP-GP, LLC","position":9,"cik":"0001777656","reported_name":"Versant Ventures VII GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-12T20:37:21.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":350000,"price":29,"value":10150000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Versant Venture Capital VII, L.P. (\"VVC VII\"). Versant Ventures VII GP-GP, LLC (\"VV VII GP\") is the sole general partner of Versant Ventures VII GP, L.P. (\"VV VII\") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":1248789,"source":{"system":"sec-edgar","filing":"0000950170-25-085490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017025085490/ownership.xml","form_type":"4"}},{"id":1115130,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T23:43:00.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the grant of a stock option to Zachary Scheiner pursuant to the Issuer's Outside Director Compensation Policy (the \"Policy\").  One hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026, subject to Dr. Scheiner's continuing to be an Outside Director (as defined in the Policy) through such applicable date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Under Dr. Scheiner's arrangement with the Adviser, Dr. Scheiner holds the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Scheiner is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."}],"balance_after":13500,"derivative":{"exercise_price":30,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001415889-25-016757","document":"form4-06112025_110656.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000141588925016757/form4-06112025_110656.xml","form_type":"4"}},{"id":1115131,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38205,"kind":"person","name":"George Jeffrey P.","position":1,"cik":"0001796789","reported_name":"George Jeffrey P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T21:46:47.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026."}],"balance_after":13500,"derivative":{"exercise_price":30,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001815776-25-000048","document":"wk-form4_1749678400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000048/wk-form4_1749678400.xml","form_type":"4"}},{"id":1115129,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T21:46:36.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026."}],"balance_after":13500,"derivative":{"exercise_price":30,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001815776-25-000047","document":"wk-form4_1749678389.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000047/wk-form4_1749678389.xml","form_type":"4"}},{"id":1115128,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":20769,"kind":"person","name":"Guerard Frederic","position":1,"cik":"0001825009","reported_name":"Guerard Frederic","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T21:46:24.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026."}],"balance_after":13500,"derivative":{"exercise_price":30,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001815776-25-000046","document":"wk-form4_1749678377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000046/wk-form4_1749678377.xml","form_type":"4"}},{"id":1115126,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":36311,"kind":"person","name":"Thunen Shelley B","position":1,"cik":"0001297491","reported_name":"Thunen Shelley B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T21:46:13.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026."}],"balance_after":13500,"derivative":{"exercise_price":30,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001815776-25-000045","document":"wk-form4_1749678366.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000045/wk-form4_1749678366.xml","form_type":"4"}},{"id":1115127,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38203,"kind":"person","name":"MCCOLLUM JAMES W","position":1,"cik":"0001200889","reported_name":"MCCOLLUM JAMES W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T21:46:02.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026."}],"balance_after":13500,"derivative":{"exercise_price":30,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001815776-25-000044","document":"wk-form4_1749678354.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000044/wk-form4_1749678354.xml","form_type":"4"}},{"id":1115132,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38207,"kind":"person","name":"Scheiner Zachary","position":1,"cik":"0001816523","reported_name":"Scheiner Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T21:45:50.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock."}],"balance_after":13500,"derivative":{"exercise_price":30,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001815776-25-000043","document":"wk-form4_1749678343.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816523/000181577625000043/wk-form4_1749678343.xml","form_type":"4"}},{"id":1174823,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-09T19:20:28.000Z","date":"2025-04-09","kind":"exercise","planned":false,"acquired":false,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the \"2020 Plan\"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean April 26, 2021."}],"balance_after":63241,"derivative":{"exercise_price":2.08,"expiration_date":"2031-08-18","underlying":"Common Stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001815776-25-000022","document":"wk-form4_1744240821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000181577625000022/wk-form4_1744240821.xml","form_type":"4"}},{"id":1174822,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-04-09T19:20:28.000Z","date":"2025-04-09","kind":"exercise","planned":false,"acquired":true,"shares":1400,"price":2.08,"value":2912.0,"ownership":{"direct":true},"balance_after":4733,"source":{"system":"sec-edgar","filing":"0001815776-25-000022","document":"wk-form4_1744240821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000181577625000022/wk-form4_1744240821.xml","form_type":"4"}},{"id":1217564,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":35188,"kind":"person","name":"Schimmelpennink Evert B.","position":1,"cik":"0001713795","reported_name":"Schimmelpennink Evert B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-07T23:10:43.000Z","date":"2025-03-07","kind":"exercise","planned":false,"acquired":false,"shares":4200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the \"2020 Plan\"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the  2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 8, 2021."}],"balance_after":337906,"derivative":{"exercise_price":1.04,"expiration_date":"2031-03-07","underlying":"Common Stock","underlying_shares":4200},"source":{"system":"sec-edgar","filing":"0001815776-25-000011","document":"wk-form4_1741389036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000011/wk-form4_1741389036.xml","form_type":"4"}},{"id":1217563,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":35188,"kind":"person","name":"Schimmelpennink Evert B.","position":1,"cik":"0001713795","reported_name":"Schimmelpennink Evert B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Secretary"}}],"security":"Common Stock","published_at":"2025-03-07T23:10:43.000Z","date":"2025-03-07","kind":"exercise","planned":false,"acquired":true,"shares":4200,"price":1.04,"value":4368.0,"ownership":{"direct":true},"balance_after":49200,"source":{"system":"sec-edgar","filing":"0001815776-25-000011","document":"wk-form4_1741389036.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000011/wk-form4_1741389036.xml","form_type":"4"}},{"id":1304368,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:22:51.000Z","date":"2025-01-09","kind":"grant","planned":false,"acquired":true,"shares":70444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean January 9, 2025."}],"balance_after":70444,"derivative":{"exercise_price":26.34,"expiration_date":"2035-01-08","underlying":"Common Stock","underlying_shares":70444},"source":{"system":"sec-edgar","filing":"0001815776-25-000005","document":"wk-form4_1736806964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000005/wk-form4_1736806964.xml","form_type":"4"}},{"id":1304367,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":35188,"kind":"person","name":"Schimmelpennink Evert B.","position":1,"cik":"0001713795","reported_name":"Schimmelpennink Evert B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:20:45.000Z","date":"2025-01-09","kind":"grant","planned":false,"acquired":true,"shares":279100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean January 9, 2025."}],"balance_after":279100,"derivative":{"exercise_price":26.34,"expiration_date":"2035-01-08","underlying":"Common Stock","underlying_shares":279100},"source":{"system":"sec-edgar","filing":"0001815776-25-000003","document":"wk-form4_1736806836.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000003/wk-form4_1736806836.xml","form_type":"4"}},{"id":1304455,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T17:26:58.000Z","date":"2025-01-09","kind":"grant","planned":false,"acquired":true,"shares":80100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean January 9, 2025."}],"balance_after":80100,"derivative":{"exercise_price":26.34,"expiration_date":"2035-01-08","underlying":"Common Stock","underlying_shares":80100},"source":{"system":"sec-edgar","filing":"0001815776-25-000009","document":"wk-form4_1736807211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000181577625000009/wk-form4_1736807211.xml","form_type":"4"}},{"id":1304459,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70050,"kind":"person","name":"Odrich Marc","position":1,"cik":"0002015900","reported_name":"Odrich Marc","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T17:24:55.000Z","date":"2025-01-09","kind":"grant","planned":false,"acquired":true,"shares":80100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean January 9, 2025."}],"balance_after":80100,"derivative":{"exercise_price":26.34,"expiration_date":"2035-01-08","underlying":"Common Stock","underlying_shares":80100},"source":{"system":"sec-edgar","filing":"0001815776-25-000007","document":"wk-form4_1736807088.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015900/000181577625000007/wk-form4_1736807088.xml","form_type":"4"}},{"id":1329308,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-17T19:55:30.000Z","date":"2024-12-16","kind":"exercise","planned":false,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the \"2020 Plan\"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean April 26, 2021."}],"balance_after":64641,"derivative":{"exercise_price":2.08,"expiration_date":"2031-08-18","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001815776-24-000074","document":"wk-form4_1734483323.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000181577624000074/wk-form4_1734483323.xml","form_type":"4"}},{"id":1329307,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":70049,"kind":"person","name":"Olsson Shawn","position":1,"cik":"0002015796","reported_name":"Olsson Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-12-17T19:55:30.000Z","date":"2024-12-16","kind":"exercise","planned":false,"acquired":true,"shares":3333,"price":2.08,"value":6932.64,"ownership":{"direct":true},"balance_after":3333,"source":{"system":"sec-edgar","filing":"0001815776-24-000074","document":"wk-form4_1734483323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015796/000181577624000074/wk-form4_1734483323.xml","form_type":"4"}},{"id":1449982,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":35188,"kind":"person","name":"Schimmelpennink Evert B.","position":1,"cik":"0001713795","reported_name":"Schimmelpennink Evert B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-24T00:16:36.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the \"2020 Plan\"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the  2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 8, 2021."}],"balance_after":342106,"derivative":{"exercise_price":1.04,"expiration_date":"2031-03-07","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001815776-24-000051","document":"wk-form4_1721780188.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000051/wk-form4_1721780188.xml","form_type":"4"}},{"id":1449981,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":35188,"kind":"person","name":"Schimmelpennink Evert B.","position":1,"cik":"0001713795","reported_name":"Schimmelpennink Evert B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Secretary"}}],"security":"Common Stock","published_at":"2024-07-24T00:16:36.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":45000,"price":1.04,"value":46800.0,"ownership":{"direct":true},"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001815776-24-000051","document":"wk-form4_1721780188.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000051/wk-form4_1721780188.xml","form_type":"4"}},{"id":1516077,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-15T20:13:06.000Z","date":"2024-05-14","kind":"purchase","planned":false,"acquired":true,"shares":3188,"price":15.68,"value":49987.84,"ownership":{"direct":true},"balance_after":3188,"source":{"system":"sec-edgar","filing":"0001815776-24-000046","document":"wk-form4_1715803974.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000046/wk-form4_1715803974.xml","form_type":"4"}},{"id":1517663,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38203,"kind":"person","name":"MCCOLLUM JAMES W","position":1,"cik":"0001200889","reported_name":"MCCOLLUM JAMES W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-14T21:29:43.000Z","date":"2024-05-13","kind":"purchase","planned":false,"acquired":true,"shares":31332,"price":15.993,"value":501092.676,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 31,332 shares purchased in the price range of $15.96 to $16.00 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":525565,"source":{"system":"sec-edgar","filing":"0001815776-24-000044","document":"wk-form4_1715722170.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000044/wk-form4_1715722170.xml","form_type":"4"}},{"id":1561983,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:48:33.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to Dr. Zach Scheiner continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date. \"Vesting Commencement Date\" shall mean March 21, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Under Dr. Scheiner's arrangement with the Adviser, Dr. Scheiner holds the option for the benefit of the Fund and the Nexus Fund II. Dr. Scheiner is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock except to the extent of their pecuniary interest therein."}],"balance_after":27000,"derivative":{"exercise_price":15.05,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001415889-24-009077","document":"form4-03262024_120321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000141588924009077/form4-03262024_120321.xml","form_type":"4"}},{"id":1561982,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-03-26T00:48:33.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":5371,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for warrants of LENZ OpCo pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held directly by the Account."}],"balance_after":5371,"derivative":{"exercise_price":10.64,"exercise_date":"2024-03-21","expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":5371},"source":{"system":"sec-edgar","filing":"0001415889-24-009077","document":"form4-03262024_120321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000141588924009077/form4-03262024_120321.xml","form_type":"4"}},{"id":1561981,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-03-26T00:48:33.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":10580,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for warrants of LENZ OpCo pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by Nexus Fund II."}],"balance_after":10580,"derivative":{"exercise_price":10.64,"exercise_date":"2024-03-21","expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":10580},"source":{"system":"sec-edgar","filing":"0001415889-24-009077","document":"form4-03262024_120321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000141588924009077/form4-03262024_120321.xml","form_type":"4"}},{"id":1561980,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-03-26T00:48:33.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":54582,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for warrants of LENZ OpCo pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":54582,"derivative":{"exercise_price":10.64,"exercise_date":"2024-03-21","expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":54582},"source":{"system":"sec-edgar","filing":"0001415889-24-009077","document":"form4-03262024_120321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000141588924009077/form4-03262024_120321.xml","form_type":"4"}},{"id":1561979,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stockj","published_at":"2024-03-26T00:48:33.000Z","date":"2024-03-21","kind":"purchase","planned":false,"acquired":true,"shares":64971,"price":15.03,"value":976514.13,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by Nexus Fund II."}],"balance_after":694755,"source":{"system":"sec-edgar","filing":"0001415889-24-009077","document":"form4-03262024_120321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000141588924009077/form4-03262024_120321.xml","form_type":"4"}},{"id":1561978,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-26T00:48:33.000Z","date":"2024-03-21","kind":"purchase","planned":false,"acquired":true,"shares":933038,"price":15.03,"value":14023561.14,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":3319339,"source":{"system":"sec-edgar","filing":"0001415889-24-009077","document":"form4-03262024_120321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000141588924009077/form4-03262024_120321.xml","form_type":"4"}},{"id":1561977,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-26T00:48:33.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":164729,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for equity of LENZ Therapeutics Operations, Inc. (\"LENZ OpCo\") pursuant to an Agreement and Plan of Merger and Reorganization by and among LENZ OpCo, the Issuer and Generate Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Generate Merger Sub\"), as amended (the \"Merger Agreement\"). Under the terms of the Merger Agreement, on March 21, 2024, Generate Merger Sub merged with and into LENZ OpCo (the \"Merger\"), with LENZ OpCo surviving the Merger as a wholly-owned subsidiary of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held directly by the Account."}],"balance_after":164729,"source":{"system":"sec-edgar","filing":"0001415889-24-009077","document":"form4-03262024_120321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000141588924009077/form4-03262024_120321.xml","form_type":"4"}},{"id":1561976,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-26T00:48:33.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":694755,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for equity of LENZ Therapeutics Operations, Inc. (\"LENZ OpCo\") pursuant to an Agreement and Plan of Merger and Reorganization by and among LENZ OpCo, the Issuer and Generate Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Generate Merger Sub\"), as amended (the \"Merger Agreement\"). Under the terms of the Merger Agreement, on March 21, 2024, Generate Merger Sub merged with and into LENZ OpCo (the \"Merger\"), with LENZ OpCo surviving the Merger as a wholly-owned subsidiary of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by Nexus Fund II."}],"balance_after":694755,"source":{"system":"sec-edgar","filing":"0001415889-24-009077","document":"form4-03262024_120321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000141588924009077/form4-03262024_120321.xml","form_type":"4"}},{"id":1561975,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-26T00:48:33.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":2386301,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for equity of LENZ Therapeutics Operations, Inc. (\"LENZ OpCo\") pursuant to an Agreement and Plan of Merger and Reorganization by and among LENZ OpCo, the Issuer and Generate Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Generate Merger Sub\"), as amended (the \"Merger Agreement\"). Under the terms of the Merger Agreement, on March 21, 2024, Generate Merger Sub merged with and into LENZ OpCo (the \"Merger\"), with LENZ OpCo surviving the Merger as a wholly-owned subsidiary of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":2386301,"source":{"system":"sec-edgar","filing":"0001415889-24-009077","document":"form4-03262024_120321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000141588924009077/form4-03262024_120321.xml","form_type":"4"}},{"id":1561969,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":36311,"kind":"person","name":"Thunen Shelley B","position":1,"cik":"0001297491","reported_name":"Thunen Shelley B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:44:10.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 21, 2024."}],"balance_after":27000,"derivative":{"exercise_price":15.05,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001815776-24-000029","document":"wk-form4_1711413836.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000029/wk-form4_1711413836.xml","form_type":"4"}},{"id":1561974,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38203,"kind":"person","name":"MCCOLLUM JAMES W","position":1,"cik":"0001200889","reported_name":"MCCOLLUM JAMES W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:42:24.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 21, 2024."}],"balance_after":27000,"derivative":{"exercise_price":15.05,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001815776-24-000028","document":"wk-form4_1711413733.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000028/wk-form4_1711413733.xml","form_type":"4"}},{"id":1561973,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38203,"kind":"person","name":"MCCOLLUM JAMES W","position":1,"cik":"0001200889","reported_name":"MCCOLLUM JAMES W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2024-03-26T00:42:24.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":6575,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"Warrant assumed in connection with the closing of the transactions contemplated by the Merger Agreement, in exchange of an outstanding warrant to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement."}],"balance_after":6575,"derivative":{"exercise_price":10.64,"exercise_date":"2020-10-30","expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":6575},"source":{"system":"sec-edgar","filing":"0001815776-24-000028","document":"wk-form4_1711413733.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000028/wk-form4_1711413733.xml","form_type":"4"}},{"id":1561972,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38203,"kind":"person","name":"MCCOLLUM JAMES W","position":1,"cik":"0001200889","reported_name":"MCCOLLUM JAMES W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-26T00:42:24.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":16633,"price":15.0299,"value":249992.3267,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares issued upon the closing of the private placement financing under the Subscription Agreement by and among the Issuer, the Reporting Person and the other purchasers party thereto, dated as of November 14, 2023, pursuant to which, immediately following the closing of the transactions contemplated by the Merger Agreement, such purchasers purchased an aggregate of 3,559,565 shares of Common Stock at a price of $15.0299 per share for aggregate gross proceeds to the Issuer of approximately $53.5 million, as more fully described in the Issuer's reports filed with the Securities and Exchange Commission."}],"balance_after":494233,"source":{"system":"sec-edgar","filing":"0001815776-24-000028","document":"wk-form4_1711413733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000028/wk-form4_1711413733.xml","form_type":"4"}},{"id":1561971,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38203,"kind":"person","name":"MCCOLLUM JAMES W","position":1,"cik":"0001200889","reported_name":"MCCOLLUM JAMES W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-26T00:42:24.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":477600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the \"Merger Agreement\"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation (\"LENZ OpCo\"), in exchange of outstanding shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement."}],"balance_after":477600,"source":{"system":"sec-edgar","filing":"0001815776-24-000028","document":"wk-form4_1711413733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000028/wk-form4_1711413733.xml","form_type":"4"}},{"id":1561970,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38203,"kind":"person","name":"MCCOLLUM JAMES W","position":1,"cik":"0001200889","reported_name":"MCCOLLUM JAMES W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-26T00:42:24.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":95034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the \"Merger Agreement\"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation (\"LENZ OpCo\"), in exchange of outstanding shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement."}],"balance_after":95034,"source":{"system":"sec-edgar","filing":"0001815776-24-000028","document":"wk-form4_1711413733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000028/wk-form4_1711413733.xml","form_type":"4"}},{"id":1561967,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":20769,"kind":"person","name":"Guerard Frederic","position":1,"cik":"0001825009","reported_name":"Guerard Frederic","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:40:57.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 21, 2024."}],"balance_after":27000,"derivative":{"exercise_price":15.05,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001815776-24-000027","document":"wk-form4_1711413647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000027/wk-form4_1711413647.xml","form_type":"4"}},{"id":1561966,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":20769,"kind":"person","name":"Guerard Frederic","position":1,"cik":"0001825009","reported_name":"Guerard Frederic","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:40:57.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":23571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the \"Merger Agreement\"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation (\"LENZ OpCo\"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan)  through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 6, 2023."}],"balance_after":23571,"derivative":{"exercise_price":6.04,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":23571},"source":{"system":"sec-edgar","filing":"0001815776-24-000027","document":"wk-form4_1711413647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000027/wk-form4_1711413647.xml","form_type":"4"}},{"id":1561965,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":20769,"kind":"person","name":"Guerard Frederic","position":1,"cik":"0001825009","reported_name":"Guerard Frederic","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:40:57.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":30897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the \"Merger Agreement\"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation (\"LENZ OpCo\"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan)  through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean September 17, 2021."}],"balance_after":30897,"derivative":{"exercise_price":2.08,"expiration_date":"2031-09-16","underlying":"Common Stock","underlying_shares":30897},"source":{"system":"sec-edgar","filing":"0001815776-24-000027","document":"wk-form4_1711413647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000027/wk-form4_1711413647.xml","form_type":"4"}},{"id":1561985,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38207,"kind":"person","name":"Scheiner Zachary","position":1,"cik":"0001816523","reported_name":"Scheiner Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:40:09.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 21, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus II Fund, L.P. (the \"Nexus II Fund\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund, the Nexus II Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":27000,"derivative":{"exercise_price":15.05,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001415889-24-009073","document":"form4-03262024_120359.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816523/000141588924009073/form4-03262024_120359.xml","form_type":"4"}},{"id":1561968,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38204,"kind":"person","name":"Drapkin Kimberlee C","position":1,"cik":"0001340881","reported_name":"Drapkin Kimberlee C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:39:32.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 21, 2024."}],"balance_after":27000,"derivative":{"exercise_price":15.05,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001815776-24-000026","document":"wk-form4_1711413562.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000026/wk-form4_1711413562.xml","form_type":"4"}},{"id":1561963,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":38205,"kind":"person","name":"George Jeffrey P.","position":1,"cik":"0001796789","reported_name":"George Jeffrey P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:38:06.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 21, 2024."}],"balance_after":27000,"derivative":{"exercise_price":15.05,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001815776-24-000025","document":"wk-form4_1711413477.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000025/wk-form4_1711413477.xml","form_type":"4"}}],"next_cursor":"2024-03-26T00:38:06.000000Z,1561963"}